Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling by Vergara, Ismael A et al.








Evolution of late-stage metastatic melanoma is dominated by aneuploidy and
whole genome doubling
Vergara, Ismael A ; Mintoff, Christopher P ; Sandhu, Shahneen ; et al ; Widmer, Daniel S ; Cheng, Phil
F ; Amann, Valerie ; Dummer, Reinhard
Abstract: Although melanoma is initiated by acquisition of point mutations and limited focal copy number
alterations in melanocytes-of-origin, the nature of genetic changes that characterise lethal metastatic
disease is poorly understood. Here, we analyze the evolution of human melanoma progressing from early
to late disease in 13 patients by sampling their tumours at multiple sites and times. Whole exome and
genome sequencing data from 88 tumour samples reveals only limited gain of point mutations generally,
with net mutational loss in some metastases. In contrast, melanoma evolution is dominated by whole
genome doubling and large-scale aneuploidy, in which widespread loss of heterozygosity sculpts the burden
of point mutations, neoantigens and structural variants even in treatment-naïve and primary cutaneous
melanomas in some patients. These results imply that dysregulation of genomic integrity is a key driver
of selective clonal advantage during melanoma progression.
DOI: https://doi.org/10.1038/s41467-021-21576-8






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Vergara, Ismael A; Mintoff, Christopher P; Sandhu, Shahneen; et al; Widmer, Daniel S; Cheng, Phil F;
Amann, Valerie; Dummer, Reinhard (2021). Evolution of late-stage metastatic melanoma is dominated
by aneuploidy and whole genome doubling. Nature Communications, 12:1434.
DOI: https://doi.org/10.1038/s41467-021-21576-8
ARTICLE
Evolution of late-stage metastatic melanoma is
dominated by aneuploidy and whole genome
doubling
Ismael A. Vergara 1,2,3, Christopher P. Mintoff2, Shahneen Sandhu2, Lachlan McIntosh1,4, Richard J. Young2,
Stephen Q. Wong2, Andrew Colebatch2, Daniel L. Cameron 1,5, Julia Lai Kwon2, Rory Wolfe 6,
Angela Peng2,7, Jason Ellul 2, Xuelin Dou2, Clare Fedele2, Samantha Boyle2, Gisela Mir Arnau 2,
Jeanette Raleigh2, Athena Hatzimihalis 2, Pacman Szeto 2,7, Jennifer Mooi2, Daniel S. Widmer8,
Phil F. Cheng 8, Valerie Amann8, Reinhard Dummer 8, Nicholas Hayward 3,9, James Wilmott 3,
Richard A. Scolyer 3,10,11, Raymond J. Cho12, David Bowtell2,13, Heather Thorne2, Kathryn Alsop2,
Stephen Cordner14, Noel Woodford14, Jodie Leditschke14, Patricia O’Brien14, Sarah-Jane Dawson 2,15,
Grant A. McArthur2,13, Graham J. Mann 3,16, Mitchell P. Levesque8, Anthony T. Papenfuss 1,2,4,5,13,18✉ &
Mark Shackleton 2,7,13,17,18✉
Although melanoma is initiated by acquisition of point mutations and limited focal copy
number alterations in melanocytes-of-origin, the nature of genetic changes that characterise
lethal metastatic disease is poorly understood. Here, we analyze the evolution of human
melanoma progressing from early to late disease in 13 patients by sampling their tumours at
multiple sites and times. Whole exome and genome sequencing data from 88 tumour
samples reveals only limited gain of point mutations generally, with net mutational loss in
some metastases. In contrast, melanoma evolution is dominated by whole genome doubling
and large-scale aneuploidy, in which widespread loss of heterozygosity sculpts the burden of
point mutations, neoantigens and structural variants even in treatment-naïve and primary
cutaneous melanomas in some patients. These results imply that dysregulation of genomic
integrity is a key driver of selective clonal advantage during melanoma progression.
https://doi.org/10.1038/s41467-021-21576-8 OPEN
1 Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. 2 Peter MacCallum Cancer Centre, Melbourne, VIC,
Australia. 3Melanoma Institute of Australia, Sydney, Australia. 4Department of Mathematics and Statistics, The University of Melbourne, Parkville, VIC,
Australia. 5Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia. 6 School of Public Health and Preventive Medicine, Monash
University, Melbourne, Australia. 7Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
8Department of Dermatology, University of Zürich Hospital, Zürich, Switzerland. 9QIMR Berghofer Medical Research Institute, Brisbane, Australia. 10Tissue
Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia. 11 Sydney Medical School, The University of Sydney, Sydney, Australia.
12Department of Dermatology, University of California, San Francisco, CA, USA. 13 Sir Peter MacCallum Department of Oncology, The University of
Melbourne, Parkville, VIC, Australia. 14The Victorian Institute of Forensic Medicine, Melbourne, Australia. 15Centre of Cancer Research, The University of
Melbourne, Parkville, VIC, Australia. 16Centre for Cancer Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
17Department of Oncology, Alfred Health, Melbourne, Australia. 18These authors contributed equally: Anthony T Papenfuss, Mark Shackleton
✉email: papenfuss@wehi.edu.au; mark.shackleton@monash.edu













alignant transformation in cutaneous melanocytes is
typically initiated by acquisition of single nucleotide
variants (SNVs) resulting from ultra-violet (UV) light-
induced DNA damage. The most common SNVs, which are even
found in pre-neoplastic nevi1–3, constitutively activate the BRAF
kinase or NRAS GTPase, although deleterious SNVs that impair
tumour suppression by NF1 are also frequently detected4,5. For
each of these major genotypic variants, concurrent point muta-
tion affecting other genes is often thought to be required for the
full invasive phenotype of melanoma6–11.
The role of structural variants (SVs; see Methods for defi-
nition) in melanoma is less well defined, although a subset of
melanomas appears driven by oncogenic fusions12,13. Copy
number alterations (CNAs), including deletions of the
CDKN2A tumour suppressor and amplifications of BRAF, arise
infrequently in nevi but are more abundant in invasive
melanoma6,14. This suggests that the development of genomic
instability is a key event in melanomagenesis, potentially
facilitating allelic imbalances that support maintenance and
progression of disease. However, understanding is limited of
the mutational events that facilitate metastasis and the evolu-
tion of typically fatal late disease.
Previous studies have identified continued acquisition of both
SNVs and SVs during cancer progression15–18. Consistent with
this, in relatively limited sampling, an array of genetic changes
was observed to develop over time within treatment-naïve mel-
anomas in individual patients6,14,19, as well as during evolution of
therapy resistance20,21. These included new SNVs as well as focal
allelic amplifications and deletions, suggesting that melanoma
progression is fuelled by mutations other than those classically
induced by UV mutagenesis.
To address this and to overcome the challenges of obtaining
multiple metastatic tissues from the same patients, the CASCADE
(CAncer tiSsue aCquisition After Death) rapid autopsy pro-
gram22 was established, enabling sampling of end-stage cancers.
In this study, using tumour and blood samples from 7 melanoma
patients enroled in CASCADE, as well as data from 6 patients
from previous studies19,21, we characterised somatic mutational
processes linked to end-stage melanoma. We found that although
gain of SNVs is generally limited in melanoma progression, dis-
ease evolution is dominated by large-scale copy number changes,
including universal tetraploidization and the acquisition of
remarkable degrees of allelic imbalance highlighted by extensive
loss of heterozygosity (LOH) in some patients. These findings
implicate dysregulation of genomic integrity as a key driver of
biological advantage during competitive subclonal growth in
human melanoma.
Results
Patient enrolment and sequencing. Tumour samples from seven
CASCADE melanoma patients with DNA available from normal
tissues, matched primary melanomas and/or regional metastases,
were chosen for genomic sequencing (Fig. 1A, Supplementary
Figs. 1, 2A; EGA accession: EGAS00001004950). Survival times
from melanoma diagnosis to death ranged from 8 months to 12
years (Supplementary Fig. 3). All CASCADE patients had BRAF
mutant melanomas and received BRAF and/or MEK inhibitors
during their disease course, with some also receiving immu-
notherapy (Supplementary Figs. 2A, 3). For each patient, 3–6 end-
stage tumours (Supplementary Table 1) underwent whole exome
sequencing (WES) (5 patients; mean coverage 156×, range
108–256×) or whole-genome sequencing (WGS) (2 patients, mean
coverage 67×, range 40–81×). Multi-regional sampling of primary
and/or regionally metastatic disease was performed in 4 patients to
assess intra-tumoural heterogeneity (Fig. 1A, Supplementary Fig. 1).
WES was also performed on plasma obtained prior to death from 4
patients (Supplementary Fig. 3).
With permission, published WES data from matched primary
and metastatic disease from 6 additional patients were added to
the cohort (Figs. S2B and S3, Supplementary Table 2)19,21. Of
these, one had a BRAF mutant melanoma (ETH-E), two had
NRAS mutant melanomas (SK-G & ETH-J), and three were
BRAF/NRAS/NF1 wild-type (MI-F, SK-H, ETH-F; Supplemen-
tary Fig. 2B).
In total, 88 tumour samples from 13 patients were analysed.
These spanned primaries, regional metastases, distant metastases
and circulating tumour DNA and included multiple samples from
individual tumours in some cases. We defined early mutations as
those detected in the earliest available tumour tissue of each
patient. This constituted primary melanomas for 11 patients and
regional metastases for two patients. Mutations first observed in
tumours recurring subsequent to this were termed late events.
End-stage mutational events were those first observed in
metastases obtained at autopsy. Patients were first diagnosed
with disease at different stages: CAS-A, B and C presented with
Stage I disease; CAS-F, CAS-G, ETH-E, ETH-F, ETH-J and MI-F
had Stage III disease at the time of diagnosis; and CAS-E and D
had Stage IV disease at diagnosis.
Sequencing data were first surveyed for SNVs and small
insertion/deletions (indels) using an ensemble variant calling
pipeline designed to take advantage of the multiple samples per
patient (see “Methods”). Validation by targeted amplicon
sequencing of a subset of predicted SNVs and small indels
showed an accuracy of 90% (sensitivity 86%, specificity 98%)
(Supplementary Notes, Supplementary Tables 3 and 4). More-
over, highly concordant variant calling was noted from DNA
extracted from fresh frozen or formalin-fixed paraffin-embedded
(FFPE) tissue from a visceral lung metastasis from patient CAS-G
(Supplementary Notes, Supplementary Figs. 4, 5, Supplementary
Table 5). This suggested only minimal FFPE artefacts in variant
calling.
Gain and loss of somatic SNVs and small indels during mel-
anoma progression. Cutaneous melanomas typically have high
numbers of SNVs23. Consistent with this, mutational loads from
3.3 (ETH-J) to 150.1 (MI-F) mutations/Mbp were observed in
early melanomas in our cohort (Fig. 1B, C). Metastatic disease
was usually dominated by these early mutations (Fig. 1B). In each
late metastasis, loss of early mutations was apparent (median 2
mutations/Mbp) along with the emergence of new SNVs and
indels (median 2.2 mutations/Mbp). Some of the new mutations
were shared amongst other sites of late disease and some were
unique to specific sites. Shared mutational losses and gains sug-
gested evolutionary relationships between tumours.
In order to understand mutational processes in melanoma
evolution, we estimated mutational signatures in early and late
disease in each patient (see “Methods”). Early mutations were
predictably dominated by UV signatures (signatures 7a and 7b)
(Fig. 2A). In contrast, mutations first observed in late disease
mostly possessed non-UV signatures, with signatures 31, 38, 39
and 58 each apparent in at least 3 patients. While the aetiology
of signature 38 is unknown, it is described as found exclusively
in UV-associated melanomas. UV signature mutations also
emerged in late disease in 8 patients, likely derived from low
abundance subpopulations in early disease that seeded distant
metastases.
In two patients (CAS-G and SK-H), metastatic disease was
dominated by signature 11 (sometimes referred to as the
temozolomide signature). Interestingly, although patient CAS-G
had previously been treated with temozolomide, signature
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11 mutations were evident in this patient’s lung and bowel but
not liver metastases. Patient SK-H did not receive systemic
therapy prior to tumour sampling19. In these patients, the
signature 11 mutation loads in metastatic disease were coincident
with predicted deleterious mutations in DNA-mismatch repair
genes, including MSH6 (CAS-G and SK-H), MLH1 (CAS-G),
MLH3 (CAS-G and SK-H) and MSH3 (SK-H); mutations in
CAS-G were validated by targeted amplicon sequencing (Supple-
mentary Table 3). Signatures 6, 15 and 21—all associated with
DNA mismatch repair deficiency—were each present in two
patients (signature 6: patients ETH-E and ETH-F; signature 15:
patients ETH-J, CAS-C; signature 21: patients SK-G, CAS-B).
These findings implicate DNA repair deficiency as a major















































































































































































































































































































































































































































































































































DM5 Brain - hippocampus
DM6 Brain - left parietal lobe
RM Regional lymph node metastasis
Liver metastases
  DM2 - right lobe
  DM3 central lobe
  DM4 left lobe
DM1 Pouch of Douglas
P1 Core 1 P3 Core 3 P2 Core 2
Primary - skin right lower back
Fig. 1 Temporal and multi-regional spatial sampling reveals limited acquisition of point mutations during melanoma progression to end-stage disease.
A Spatial distribution of pre-mortem and autopsy samples for CASCADE patient CAS-D. Created with BioRender.com. B Unique SNVs and small indels
detected across tumours from each patient. The identifier for each sample is described in Tables S1 and S2. Y-axis indicates the number of mutations in
each patient. C Mutational load of SNVs and small indels across tumours from each patient. Y-axis is shown in a logarithmic scale.
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We interrogated the data from early disease for mutations in
genes recurrently mutated in melanoma5 or in the COSMIC
database (Fig. 2B and Supplementary Table 6), identifying BRAF
(n= 8 patients), FAT4 (n= 6), TP53 (n= 4), KMT2C (n= 4),
GRIN2A (n= 6), NRAS (n= 2),WRN (n= 4) and ARID2 (n= 4)
amongst the genes most commonly affected (Fig. 2B). The vast
majority of SNVs in early disease were present in all
metastatic sites.
We also identified cancer-associated genes that were mutated
only in late disease (Fig. 2B), particularly in the two patients with
impaired DNA repair, CAS-G and SK-H, whose rates of gained
mutation across all metastases were 108 and 202 mutations/Mbp
respectively. These included two independent mutations in
PIK3CA24 in the lung (DM6, E542K mutation) and small bowel
(DM4, E545K mutation) metastases of patient CAS-G (Fig. 2C).
In patient CAS-C, mutations in CTNNB1, which is linked to
melanoma metastasis19,25, were found exclusively in brain
metastases at residues P44 and S45, both of which regulate
beta-catenin26. Residues E542 and E545 in PIK3CA, and S45 in
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Fig. 2 Timing of mutational processes and candidate drivers shows UV damage and DNA repair dysfunction dominate in chronologically distinct
phases. A Mutational signatures in early and late disease. Shown signatures, represented by COSMIC identifiers, were identified in at least 2 patients.
Vertical lines indicate the normalised inferred weight per patient with the indicated signature in early (upper) and late (lower) disease. B Recurrently
mutated melanoma or COSMIC cancer genes in early or late disease. Shown genes were mutated in at least 2 patients and are presented in decreasing
number of patients. Dotted mutations indicate predicted deleterious or COSMIC mutations. C Distribution of hotspot mutations27 across the cohort.
Mutations surrounded by black indicate those occurring in late disease.
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PIK3CA, which is associated with parallel subclonal evolution in
melanoma14 and centrosome amplification28, was the gene that
most commonly (n= 3 patients) acquired a hotspot mutation in
late disease (Fig. 2C, Supplementary Table 7).
Apart from these examples, SNVs in cancer-associated genes
appeared de novo in metastases only infrequently. Indeed, loss in
late disease was seen in all patients of SNVs and indels present in
early disease, such that no consistent net acquisition of these
mutations was observed in the 11 patients without defective DNA
mismatch repair.
Acquisition of allelic imbalance and loss of heterozygosity.
Apparent loss of SNVs and indels can be caused by a number of
processes: deletion of one or more copies of an allele including
LOH, reversion of mutations, dominance in metastases by sub-
clones without mutations, and genetic heterogeneity in ante-
cedent tumours not inherited by later metastases or acquired at
the site of origin after dissemination of metastatic cells29. To
better discern processes underlying loss of mutations, allele-
specific copy number (CN) was estimated in our dataset.
Acquisition of allelic imbalance (AI), including LOH, was
evident in all sites of disease in all patients (Fig. 3A, left and
middle panels) and typically involved whole chromosomes or
chromosomal arms. In early disease, the extent of AI varied
widely from 5.4% (patient CAS-G) to 83.6% (SK-H) of the
genome (Fig. 3A, left panel). In all patients, melanoma evolution
was characterised by increasing AI either subclonally in early
disease (e.g. multiple primary cores in patients CAS-D, ETH-J) or
in subsets of metastatic samples (e.g. lesions in CAS-C, ETH-F).
In some patients (CAS-D, ETH-E and SK-H), about 50% of the
genome in late disease was affected by LOH.
Co-occurrence of SNV/indel loss and deletions was identified
between early to late disease. LOH explained a significant
proportion of lost SNVs and indels in late disease (Fig. 3A, right
panel). Mutations lost in late disease and located in regions of
retained heterozygosity had lower cancer cell fractions (in early
disease) compared to those lost in regions of acquired LOH
(Supplementary Fig. 6). This supports the hypothesis that these
mutations were not present in the subclone that seeded the
metastasis. This group could also have included mutations
acquired in regions of copy number gain, where the mutated
allele was subsequently lost. While mutations lost in regions of
acquired LOH were mostly associated with the UV-induced
mutational process with no other recurrent signatures (Supple-
mentary Fig. 7), those lost in other regions were less well
explained by this mutagen. Instead, multiple other mutational
processes were observed in this group. For example, the presence
of signatures 6 and 11 in patient CAS-G, signature 11 in MI-F
and signature 14 in CAS-E suggested DNA-mismatch repair
defects may have also occurred in early disease in these patients
(Supplementary Fig. 8). This suggests that acquisition of somatic
mutations via DNA repair deficiency may not only be common in
late disease (Fig. 2A) but also occur subclonally in early
melanoma.
Within each patient, allele-specific copy number alterations
(CNAs) typically involved the same alleles, suggesting common
origins of these clones. However, akin to observations in lung
cancer30, different alleles in distinct metastases were occasionally
involved. In two liver metastases from patient CAS-G, chromo-
some 15 acquired LOH by independent deletion events affecting
different alleles (Supplementary Fig. 9). Similarly, in patient CAS-
B, chromosome 10 acquired LOH by deletion of different alleles
in regional and visceral metastases (Fig. 3B). Mirrored AIs such as
these might reflect convergent evolution driven by continued
chromosomal instability and selection for gene dosage30, effects
of varied selective pressures in distinct environments, or selective
deletion of different subclonal mutations.
As LOH events accounted for a major proportion of lost
mutations in late disease (Fig. 3A, right panel), we wondered
whether deletion of disadvantageous non-synonymous mutations
or neoantigens might favour selection of LOH. Indeed, LOH
might provide an efficient mechanism to improve the fitness of
melanoma cells through the removal of multiple deleterious
mutations and/or by eliminating multiple neoantigenic SNVs in
single mutational events.
Of the 506 LOH segments acquired across all patients, 157
(31%) deleted at least one non-synonymous mutation (Supple-
mentary Fig. 10A). As LOH segments that did not delete non-
synonymous variants tended to be smaller (Supplementary
Fig. 10B), possibly resulting from over-segmentation in copy
number estimation (Supplementary Fig. 10C), we considered only
segments greater than 10Mb (n= 194).
We reasoned that if LOH provides a fitness advantage by
selective deletion of disadvantageous non-synonymous muta-
tions, we might observe the preferential loss of regions with a
higher than the expected number of non-synonymous mutations,
which can be estimated from the number of synonymous
mutations and human codon usage frequencies (see Supplemen-
tary Material). Across all patients, only 67/194 large acquired
LOH segments deleted more non-synonymous mutations than
expected, which is not more frequent than expected by chance (p
= 0.8, one-sided binomial test; see Supplementary Methods). This
does not support a dominant role for removal of highly mutated
regions, but does not rule out selective loss of individual
mutations impacting fitness.
We next considered the potential role of neoantigens resulting
from SNVs in early disease by predicting neoantigens for patient-
specific HLA-A, -B and -C alleles using NetMHC4.031,32
(see Supplementary Methods) and examining the loss of these
predicted neoantigens due to LOH in late disease. We found
between 43 and 2109 predicted neoepitopes with weak or strong
HLA class I binding affinity in each patient (median 217) in early
disease. Of these, 18–985 (median 107) occurred in genes
commonly expressed in melanoma (see Supplementary Methods).
To evaluate the extent to which acquired LOH events delete
predicted expressed neoantigens, we collected overlapping LOH
segments into events by comparing late disease samples within
each patient. Patients lost from 2 (CAS-A) to 18 (CAS-D)
predicted expressed neoantigens due to LOH. Thirty-nine LOH
events removed from 1 to 10 (CAS-D) predicted expressed
neoantigens, with 19 removing from 2 or more (Fig. 3C,
Supplementary Table 8). Patients lost from 2 (CAS-A) to 18
(CAS-D) predicted expressed neoantigens due to LOH. Thirty-
nine LOH events removed from 1 to 10 (CAS-D) predicted
expressed neoantigens, with 19 removing from 2 or more (Fig. 3C,
Supplementary Table 8). This highlights that large-scale LOH
may provide an efficient mechanism to remove expressed
neoantigens, or regions with high neo-antigenicity, in single
mutational events. However, it is important to note that acquired
LOH may reduce only a small proportion of the overall
neoantigen load, as we observed.
These observations led us to consider if some regions in
individual patients might demonstrate a preference for deletion
of neoantigens over non-neoantigenic non-synonymous muta-
tions, or vice versa. To test this, we looked for regions of LOH
where high predicted neo-antigenicity and high rates of non-
synonymous mutations were mutually exclusive, finding no
such inverse association in 7 of 8 patients tested (Supplemen-
tary Table 9), although several patients could not be tested due
to low numbers of mutations. Of these, 2 (CAS-F and ETH-J)
only lost regions with high predicted neo-antigenicity.
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Interestingly, one patient, CAS-D, showed strong mutual
exclusivity (p= 0.02, two-sided Barnard’s test) with 22 LOH
regions with high predicted neoantigenity and low rates of non-
synonymous mutations, and 13 LOH regions with low
predicted neo-antigenicity and high numbers of non-
synonymous mutations.
These results fall short of demonstrating a dominant role for
the sculpting by LOH of non-synonymous mutations or
neoantigens, but leave open the possibility that selection for
deletion of specific mutations may account for large-scale LOH in
some patients. Certainly, other factors may influence the selection
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affected transcripts and the presence of advantageous mutations
whose deletion may be selected against. Additionally, reduction of
the allelic load of non-synonymous or neoantigenic mutations
through the acquisition of allelic imbalance was not considered.
Despite the above, mutations lost in regions of acquired LOH
possessed other properties that might suggest enhanced neo-
antigenicity. In some patients, deleted predicted strong binding
neoantigenic mutations occurred in genes with higher expression
(Supplementary Fig. 11). Also, predicted neoepitopes lost due to
LOH frequently had higher estimated cancer cell fraction in early
disease than those lost through other mechanisms (Supplemen-
tary Fig. 12: CAS-A, CAS-B, CAS-C, CAS-D, CAS-E, CAS-F, SK-
G, SK-H) and possessed stronger predicted binding affinity to
specific HLA alleles in some cases (Supplementary Fig. 13: CAS-D
HLA-C:06:02, CAS-F HLA-B:44:03, SK-G HLA-B:07:02 SK-G).
Although neoantigen prediction has poor specificity for predict-
ing immunogenicity33,34, these data support the idea that LOH
events might provide a more efficient means than individual SNV
reversions for clonal immuno-editing35.
As structural variants (SVs), such as gene fusions are
increasingly recognised oncogenic drivers in melanoma12,13, we
also examined the impact of LOH on SVs by analysing WGS data
obtained from patient CAS-D. Several SVs observed in chromo-
somes 2 and 4 in the left liver metastasis were absent from the
central liver lesion with coincident LOH. Similarly, the extension
of LOH in chromosome 10 of the central liver lesion coincided
with loss of SVs (Fig. 3D). This was not detectable in ctDNA,
which nevertheless represented the most abundant SVs across late
disease sites (Supplementary Fig. 14). LOH can thus shape not
only the burden of SNVs and indels, but also SVs. While the
selective subclonal advantage of individual LOH events is hard to
predict, these observations highlight the possibility that such
changes sculpt the broad mutational landscape of cancer
genomes.
Increased ploidy dominates the landscape of end-stage mela-
noma. We next considered total copy number (Fig. 4A). Con-
sistent with observations of LOH and AI, CNAs in late disease
were often large-scale and generally detectable in ctDNA. They
were also frequently manifest as amplifications (Fig. 4A, left
panel), such that the mean ploidy across late disease was 2.9
(range 1.6–4.2).
Largely diploid (mean 2, range 1.6 – 3.3) early disease was
observed in patients CAS-B, CAS-C, CAS-D, CAS-G, MI-F, SK-G
and ETH-E. Across these cases, increased ploidy was not usually
seen until the development of distant metastases. However, in
patients CAS-B and CAS-D, increased ploidy occurred subclon-
ally in regional metastases and primary sites of earlier disease,
respectively. Increased ploidy (mean 3.4, range 2.7–3.8) was
observed in the early disease of all other patients, in which it was
at least maintained in all but one metastasis (patient ETH-F,
tumour DM5), which may have been seeded independently from
a lower ploidy ancestor. Across this cohort, chromosomes 1q, 6p,
7, 8q, 13q, 15q, 20, 21q, and 22q were recurrently amplified
(Fig. 4A, right panel), suggesting net selective advantage of
increased expression of genes in those regions, including BRAF,
RAC1 and MET on chromosome 7, AKT3 on chromosome 1q
and MYC on chromosome 8q. The presence of large CNAs in
treatment-naïve melanomas indicates that such changes can
occur independently of treatment.
Predicted ploidy changes were validated in 6 patients by
fluorescence in situ hybridisation (FISH) using probes against
MYC, CDKN2A, and CCND1, and against centromeres in
chromosomes 8, 9 and 11 (r= 0.76, Spearman correlation;
Fig. 4B). In patient CAS-B, the increased copy number in visceral
metastases of the brain and the lung was confirmed by probes for
MYC and the chromosome 8 centromere (Fig. 4C). Further, FISH
to CDKN2A confirmed a hemizygous deletion affecting 9p21.3 in
the primary melanoma and diploidy of the same region in
metastases (not shown). For patient CAS-D, the prediction of
ploidy differences between spatially distinct cores of the primary
melanoma was supported by FISH to MYC and the chromosome
8 centromere (Supplementary Fig. 15). Increased ploidy was also
observed in a distant liver metastasis of CAS-D, based on FISH to
MYC and CCND1 (Supplementary Figs. 15, 16). Indeed, probe
counts for CCND1 suggested intra-tumoural heterogeneity in this
metastasis, with a dominant clone carrying 5 copies of CCND1
and a minor clone (10% of cells) carrying 8 copies (Supplemen-
tary Fig. 16).
A striking case of disagreement in copy number between
predicted and FISH-observed copy number was noted in a brain
metastasis of CAS-C (Fig. 4B and Supplementary Fig. 17), in
which average probe counts for MYC and CCND1 were 7.2 and
12.4 respectively. Assessment of this metastasis revealed extensive
heterogeneity, with sub-clones that carried either no copies or a
mode of 8 copies of MYC, and a separate population of very large
cells (~27% of total cells) each with >30 copies of MYC
(Supplementary Fig. 17). Amplifications of this magnitude have
been reported in melanoma36 and may be due to extra-
chromosomal DNA37.
Near-ubiquitous tetraploidization in late melanoma. Tumours
with increased ploidy were typically characterised by large-scale
chromosomal CNAs ranging from 2–4 copies. Although this
might be explained by the stochastic acquisition of multiple
amplifications, we wondered whether such ploidy change more
likely resulted from whole-genome doubling (WGD) events that
occurred against a background of smaller-scale stochastic
amplifications and deletions. To test this, we developed two
branching process-based models (see Methods): one modelled
aneuploidy only and the other modelled aneuploidy together with
a single WGD event. We used the Akaike Information Criteria
(AIC) to penalise for the extra parameter in the genome doubling
model and determine which model better explained the data.
In this analysis, increased ploidy was better explained by the
combination of WGD together with chromosomal or arm-level
CNAs (Fig. 4D). Indeed, every patient showed evidence of WGD.
Multi-regional analysis of two primary melanomas (samples P2 in
Fig. 3 Widespread allelic imbalance (AI) and loss of heterozygosity (LOH) in metastatic melanoma. A Left: genomic proportions of each tissue sample
affected by allelic imbalance. Horizontal bars indicate the fraction of each genome with the indicated allelic state.Middle: allelic imbalances in each sample
at the cytogenetic band level. Regions of allelic balance have the same paternal and maternal allele copy number; regions of AI have different allele-specific
copy numbers. AIs including an LOH event are shown separately. Undetermined regions are indicated in grey. Right: relationship between LOH and
mutations lost during disease progression. Shown are proportions of all lost mutations that co-occur with acquisition of LOH events. B B-allele frequencies
of single nucleotide polymorphisms in regional and distant metastases in patient CAS-B. A mirrored imbalance of heterozygous SNPs on chromosome 10
was evident between these lesions. C The impact of LOH events on neoantigenic mutations. Analysis of predicted neoantigenic mutations lost via LOH
events across the cohort. X-axis indicates the number of neoantigenic mutations lost per LOH event. D Impact of LOH events on structural variants (SVs).
Shown are Circos plots of large SVs detected in two liver metastases in patient CAS-D. Inner track indicates the allelic state for each chromosome.
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CAS-D and P1 in ETH-J) indicated that WGD can be an early
subclonal event in melanoma (Fig. 4A, D). In contrast, CAS-C
possessed only one tumour at post-mortem, a brain metastasis,
which had undergone WGD. Although WGD was reflected in
ctDNA from three patients, WGD in patient CAS-C was private
to the brain metastasis.
The observation of near-universal genome doubling together
with aneuploidy across patients supports the hypothesis that these
mechanisms provide an advantage to tumour cells. Tetraploidiza-
tion may act as an efficient mechanism to achieve high levels of
aneuploidy that increase the biological tolerance of deletion
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homozygous losses, which can lead to subpopulations with
decreased fitness. Interestingly, multiple oncogenes were found
amplified within LOH regions at a copy number beyond that
expected given the ploidy of the lesion (Supplementary Fig. 18).
These include genes that drive oncogenicity via amplification40
such as LMO1 (4 patients), CCND1 (3 patients), MYCN (2
patients) as well as MYC, MDM2, MDM4 and NKX2-1 (1
patient). Oncogenes linked to melanoma progression were also
amplified, including NRAS, KIT and RAC1, the latter highly
amplified in four patients in regions with LOH at copy numbers
of 5 (patient ETH-F), 6 (patients CAS-E and SK-H) and 7
(patient CAS-F). This suggests amplification of the remaining
allele in regions of LOH may confer selective advantage to the
tumour via over-expression of driver genes.
Mutations in genes that regulate genomic integrity. Due to the
high level of CNAs in late melanoma, we also considered muta-
tions in genes that regulate genomic integrity41–44, cell cycle
and DNA repair (Supplementary Table 10, Fig. 5A). Deleterious
TP53 mutations, which are associated with tolerance of aneu-
ploidy45, were acquired early in four patients (Fig. 5A) and in late
disease in two others. Interestingly, amplification of wild-
type MYC was also observed in two of these patients, CAS-D
and CAS-B, providing a mutational combination proposed to
Fig. 4 Ubiquitous hyperploidy in metastatic melanoma. A Left: genomic proportions of each tissue sample affected by copy number alterations (CNAs).
Horizontal bars indicate the fraction of each genome with the indicated allelic copy number. Regions with total CN > 5 are represented by the same colour.
Grey regions indicate undetermined CN. Right: CNAs in each sample at the cytogenetic band-level. B Validation of CN in 6 patients using Fluorescence In
Situ Hybridisation (FISH). X-axis corresponds to the total CN of the segment overlapping the FISH probe predicted from sequencing data. Y-axis
corresponds to the average CN across cells in each sample, determined by manual counting, for the indicated FISH probe. Centromeric probes
corresponded to chromosomes 8, 9 and 11 as controls for probes for MYC, CDKN2A and CCND1, respectively, in those chromosomes. Cen: Centromeric
probe. C FISH showing MYC amplification in two metastases from patient CAS-B, compared to the primary tumour (left). Arrow heads indicate cells with
red (Myc) and green (centromere) signals. Scale bar = 10um. CTR: Centromere probes for chromosome 8. D Widespread genome doubling in melanoma.
For each sample, the bar length indicates the Akaike Information Criteria (AIC) score obtained via branching process analyses of aneuploidy with genome
doubling (left) versus aneuploidy alone (right). Solid circles indicate the most likely scenario for each sample.
ETH−J ETH−E ETH−F CAS−A CAS−B CAS−C CAS−D SK−G CAS−E CAS−F CAS−G MI−F SK−H



























































































































































































































































Genome Doubling No Genome Doubling














































































































































































































































































































































































































Fig. 5 Potential drivers of aneuploidy and whole genome doubling in early-stage and metastatic melanoma. A Recurrent mutations across the cohort in
genes that regulate chromosomal structural integrity, cell cycle and DNA repair. Dotted mutations indicate predicted deleterious or COSMIC mutations.
Genes included correspond to significantly mutated genes in the TCGA cohort or COSMIC cancer census genes (see Supplementary Methods). The
identifier for each sample is indicated in Tables S1 and S2. B Mutant allele fraction (MAF) of mutations gained or increased in allelic dose with increased
ploidy, in association with genome doubling, in patients ETH-E, CAS-G, CAS-D and CAS-C. Each point per gene represents a sample. MAF: estimated
fraction of mutated alleles in the tumour cells of the sample. *predicted deleterious or COSMIC mutations.
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facilitate tetraploidization46. CLTC (mitotic spindle instability),
APC (checkpoint defects, merotely) and BUB1B (checkpoint
defects) were also amongst genes involved in regulation of
genomic integrity recurrently affected by deleterious
mutation42,43 (Fig. 5A). Mutations in genes that regulate the cell
cycle and DNA repair further suggested mechanisms of increased
CNAs: a truncating insertion in FGFR1OP, which anchors
microtubules47 (patient CAS-D) and deleterious missense muta-
tions in WRN, associated with homology-directed repair and
stability of fragile sites48, in patients CAS-C, CAS-F and MI-F.
Notably, CDKN2A underwent an in-frame deletion (COSMIC
variant COSM24418) in patient CAS-E and a hotspot P114L
substitution (COSMIC variant COSM753743) of reported func-
tional significance49 in patient CAS-F.
To identify mutations associated with hyperploidy using an
unbiased approach, we further evaluated patients for whom both
low and high ploidy samples were available, identifying SNVs
present in tetraploid but not matched diploid samples, or
increased in relative dose after tetraploidization (Fig. 5B,
Supplementary Table 11). The 63 genes identified by these
criteria across patients CAS-C, CAS-G, CAS-D, and ETH-E
regulate multiple biological processes, including signal transduc-
tion and cell differentiation (Supplementary Table 12). Mutations
were also gained in genes linked to cell cycle progression and
cytoskeletal and microtubule organisation, including SIPA150
(n= 2 patients), TACC151, SPICE152 and FRY53, amongst others
(Supplementary Table 12). While 88 samples were available,
shortcomings of our study were that the number of patients was
relatively low (13) and samples possessed a complex dependence
structure, confounding hypothesis testing. Nevertheless, these
findings suggest diverse potential drivers of disrupted genomic
integrity in melanoma progression.
Tumour phylogenies. As melanoma evolution was found to be
dominated by CNAs, we estimated allele-specific CNA-based
phylogenetic trees of spatiotemporally separated tumours and late
disease ctDNA from each of 4 patients (CAS-D, CAS-B, CAS-G,
CAS-C) whose melanomas progressed from near-diploid in early
disease to hyperploid in late disease (Fig. 6A) and in 2 patients
(SK-H, MI-F) with previously published trees19 (Supplementary
Figs. 19, 20). We also estimated phylogenetic trees from SNVs
and jointly from SNVs and copy number (Supplementary
Figs. 19–24). This provided insight to disease evolution in these
cases, including evolutionary branches on which genome dou-
bling was likely to have occurred and patterns of aneuploidy
before and after genome doubling.
Based on these analyses, we observed that metastatic disease in
patient CAS-D (Fig. 6A, left) most likely arose from the sub-clone
in the primary melanoma that underwent genome doubling (P2,
Supplementary Fig. 15). The left liver lesion (DM4) probably
developed from an early seeding from this sub-clone, as it
displayed similar allelic balance in chromosome 1q, which was
affected by LOH in all other metastatic sites (Fig. 3, Supplemen-
tary Fig. 25). The central liver lesion (DM3) in this patient
clustered closest with brain metastases, suggesting a shared
subclonal origin. A SNV-based phylogeny for this patient
(Supplementary Fig. 21) showed similar disease evolution
patterns, but reflected that the vast majority of the SNV burden
was acquired in earlier disease progression compared to CNAs.
We assumed that widespread metastases would contribute to
ctDNA mutations, however, the CNA profile of late disease
ctDNA in patient CAS-D very closely resembled the caudate lobe
liver lesion (DM2) (Fig. 6A, left). This was also observed in the
SNV phylogeny, in addition to resemblance to axillary regional
metastasis and the Pouch of Douglas lesion (DM1). This suggests
that some more than other metastases may shed tumour-
associated DNA into the circulation despite their co-location in
the same organs. A joint evidence tree based on both SNVs and
CNAs (Supplementary Fig. 21) confirmed patterns of progression
and the similarity of ctDNA.
Although genome doubling was observed universally in almost
all distant metastases (Fig. 4D and 6A), continued acquisition of
aneuploidy occurred after genome doubling in patients CAS-G,
CAS-D and CAS-B (Fig. 6A and Supplementary Figs. 22, 23).
Additionally, the timing of genome doubling varied, occurring in
the primary tumours of CAS-D (subclonally), CAS-E, SK-H,
ETH-F and ETH-J (Fig. 4D), but only observed in one brain
metastasis of CAS-C (Fig. 6A and Supplementary Fig. 24). Thus,
genome doubling is not absolutely required to permit distant
metastases, and CNAs can occur both before and after genome
doubling.
The joint SNV and CNA phylogenies for these patients
(Supplementary Figs. 21–24) retained the consistent clustering of
early versus late mutations compared to germline, as well as the
preferential grouping of ctDNA samples with specific mutations,
with differences likely the result of enhanced phylogenetic signal
when combining these data. For patients MI-F and SK-H,
previously reported phylogenies19 were in agreement with those
generated here with the same event types (Supplementary Figs. 19,
20, Supplementary Notes).
The phylogenetic reconstruction provided by MEDICC CNA-
based trees was inspected for further instances of convergent
evolution, revealing evidence of parallel evolution and reversals of
mutations by LOH, as well as mirrored allelic imbalances. For
example, we examined allele-specific copy number variants in
patient CAS-D and sought CNAs that occurred more than once
in different parts of the evolutionary tree (Supplementary Fig. 26).
Chromosome 12q was initially diploid (in P1 and P3) prior to
genome doubling and lost a copy to reach allele-specific copy
number (2, 1) within the primary (P2). This was followed by a
further gain to copy number (2, 2) and then multiple independent
losses in distant metastases to (2, 1). Similarly, the region
11q23–11q25 was also initially diploid. Following WGD (P2), it
underwent arm-level deletion to allele-specific copy number (2,
1), then independent gains in two distant metastases of the liver
to return to allele-specific copy number (2, 2).
The evidence for convergent evolution presented here is likely
an underestimate, as previous studies have illustrated parallel
acquisition of mutations through disease progression in geneti-
cally identical inter-patient cancers54 as well as in intra-patient
single-cell resolution characterisation of melanoma29. Phyloge-
nies like the ones presented here will become increasingly more
accurate with temporal-spatial sampling coupled with single-cell
resolution data and methodologies for subclonal evolutionary
history reconstruction that do not rely on the infinite sites model
assumption55.
Comparison of the timing of CNA and SNV acquisition
during melanoma development confirmed that the burden of
SNVs in late disease in each patient was mostly acquired in
early disease and did not change substantially during disease
progression (Fig. 6B), with exceptions in the two patients who
developed DNA mismatch repair defects (SK-H and CAS-G).
In contrast, the kinetics of CNA acquisition varied markedly.
All patients had at least low levels of aneuploidy in early
disease with highly recurrent full or partial loss of chromo-
somes 9 and 10. While WGD occurred in at least one tumour
in every patient, it was first observed in the early disease of 5
patients (CAS-E, SK-H, ETH-F, ETH-J, and subclonally in
CAS-D), in the regional metastases of CAS-B (subclonally),
and not until late disease in 5 patients (CAS-C, CAS-G, MI-F,
SK-G, ETH-E).
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Fig. 6 Evolution of cutaneous melanoma. A Copy number-based phylogenetic trees for patients CAS-D, CAS-B, CAS-G and CAS-C. Evolutionary relationships
between samples were derived using MEDICC, based on allele-specific copy numbers. Support values for each node were obtained by resampling of the distance
matrix. MEDICC treated genome doubling events as independent chromosomal amplifications, resulting in long branch lengths. S.B.: Small Bowel. B Summarised
genetic changes in the progression to end-stage melanoma. From top to bottom: evolution of somatic mutational load (mutations/Mbps), allelic imbalance
without LOH (% genome affected), allelic imbalance with LOH (% genome affected), average ploidy, and evidence for genome doubling (ΔAIC=AICnon-WGD-
AICWGD, where AICnon-WGD is the Akaike Information Criterion (AIC) for the model with aneuploidy only, and AICWGD is the AIC for the model that includes
WGD; ΔAIC >0 supports genome doubling) across primary melanomas and regional and distant metastases for each patient. Germline estimates are depicted as
comparative references. Yellow diamonds joining lines represent mean values for each time of disease. Each dot represents an individual tissue sample.
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Of the 11 patients for whom we analysed one or more samples
of primary cutaneous melanoma, 5 showed >15% of the genome
affected by allelic imbalance, 7 showed >15% of the genome
affected by LOH, and 5 showed ploidy >2.5. Three patients had
multi-regional sampling of their primary melanomas and all of
these showed genomic instability in at least one region. It is
possible that subclonal chromosomal instability in the primary
melanomas we evaluated was more frequent than observed due to
sampling.
Interestingly, degrees of AI and hyperploidy varied amongst
distant metastases of individual patients in the latter cohort, with
some metastatic sites showing decreased AI and reduced ploidy
compared to early disease. In contrast, the extent of LOH
increased in almost every distant metastasis (Fig. 6B), suggesting
common clonal origins of cells carrying these events. This
suggests that genomic sculpting by deletion events confers
biological advantage in melanoma.
Discussion
We performed multi-regional sampling of end-stage melanoma at
autopsy21,22. This enabled us to characterise genetic changes
associated with progressive disease, finding that tetraploidization
and acquisition of aneuploidy are dominant mutational
mechanisms across evolution to end-stage, fatal melanoma. This
contrasts with the key roles of UV-induced SNVs in melanocytic
transformation to early melanoma4,6. Although SNVs or indels
affecting genes associated with cancer were abundant in the early
melanomas of our cohort, their continued acquisition was
minimal during progression to late disease. In contrast, acquisi-
tion of CNAs was abundant. Although at least low-level aneu-
ploidy was consistently found in early disease, with recurrent
LOH in chromosomes 9 and 10, most sites of metastatic and end-
stage disease were affected by aneuploidy due to both WGD and
gain and loss of individual chromosomes or chromosome arms.
Our findings extend previous studies6,14,19,20 to illuminate the
breadth of genetic changes that drive melanoma progression
through treatment to end-stage disease.
Two patients (CAS-G and SK-H) were exceptions to the above
pattern, displaying markedly increased SNV burdens in meta-
static disease in association with acquisition of mutations in
known DNA mismatch repair genes. Indeed, across all patients,
mutational signatures associated with aberrant DNA repair were
observed in SNVs that first appeared in sites of metastatic disease.
This highlights the importance of defective DNA repair as a
mechanism that permits cancer cell adaptation in the face of
selective pressures such as anti-cancer therapy, and is consistent
with known SNV-based mechanisms of acquired resistance in
melanoma to targeted therapy56,57 and immunotherapy58.
However, loss of SNVs was also observed, often as a result of
LOH. The proportions of tumour genomes affected by LOH were
increased in almost all patients in late distant metastases, in some
cases to >50% compared to earlier disease. One potential role of
LOH may be as an efficient means for providing biological
advantage by eliminating multiple deleterious mutations and
reducing immunogenicity through deletion of neoantigens in
single mutational events. Although only limited support was
found for the possibility that LOH is a strongly selected driver of
loss of such mutations, LOH could also be detrimental if it
reduced critical gene products. In this sense, pervasive WGD,
which we observed in the vast majority of metastases in our
cohort, may protect sub-clones by providing adequate essential
proteins while at the same time permitting selective advantage
from focal deletion events.
Previous studies showed emergence of aneuploidy in early
melanocytic neoplasia that was associated with disease evolution
to the invasive and metastatic state6,14. Our data demonstrate that
WGD can also occur in untreated primary cutaneous melanomas,
in which it may develop subclonally. These findings indicate that
tetraploidization and acquisition of aneuploidy are not necessarily
consequences of the stresses to cancer cells imparted by anti-
cancer therapy or the metastatic process. Nor are they required
for metastasis and therapy resistance; one patient in our cohort
(CAS-C) harboured several late metastases that had not under-
gone WGD. Rather, such genomic derangements appear to be
widespread events in intra-tumoural evolution of melanoma that
confer competitive subclonal advantage, including via increasing
metastatic potential, presumably due to the changes they confer
in allelic doses of wild-type (WT) genes and/or genes affected by
SNVs and indels.
Pan-cancer studies59–61 have shown that hyperploidy is pre-
valent in cancer and associated with WGD in an estimated 37% of
cases61. In in silico modelling38, an apparently optimal state of
triploidy in cancer was achieved more efficiently by initially tet-
raploid cells than by diploid cells, presumably as a result of the
ability of the former to buffer lethal events such as nullisomy.
This is consistent with the mode of 72 chromosomes per cell
observed in the Mitelman Database38 and the mean ploidies in
our cohort of 2.9 in late metastases and 3.4 in high ploidy early
primary melanomas.
While tetraploidization is a genome-wide event, AIs acquired
through disease progression in our cohort targeted specific
chromosomes. We hypothesise that selection of region-specific
AIs is favoured because mutations in those regions modulate a
competitive growth advantage. Accordingly, an allele carrying a
mutation that is beneficial would be selected for amplification,
and/or the corresponding WT allele might be reduced or lost (e.g.
via LOH). Both events increase proportional dosage of the
advantageous mutation. In contrast, mutations that are biologi-
cally deleterious and/or immunogenic would be diluted by
amplification of the complementary WT allele or loss of the
mutated allele.
This model also predicts that mutations enriched in tumours as
a consequence of AI will support the malignant phenotype.
Consistent with this, we observed gain or increased dosage of
numerous mutated genes in metastatic tumours in transition
from diploid to hyperploid states. These genes notably included
regulators of cell cycle progression and the maintenance of
genomic integrity, which are manifestly perturbed in a high
proportion of progressing melanomas. It will be important to
validate these genes functionally as potential regulators of aneu-
ploidy in melanoma that might inform therapeutic opportunities.
Interestingly, stochastic deregulation of wild-type regulators of
genomic integrity, such as the MYC amplifications we observed
with concurrent TP53 mutations, might compound enrichment
of mutations that fuel aneuploidy.
Our data also raise the possibility that WGD and/or the
enhanced tolerance it confers to continued acquisition of AI,
might have prognostic significance in melanoma. Aneuploidy has
been proposed by some to increase the probability of recurrence
after treatment for early melanoma62,63. Moreover, the rate of
acquisition of aneuploidy, as represented by subclonality of
CNAs, was linked to survival outcomes in non-small cell lung
cancer30. In this case, the reliable detectability we observed by
ctDNA of dominant patterns of tetraploidization and aneuploidy
in metastatic melanoma could indicate a useful, minimally
invasive and prognostically important means of monitoring for
key stages of disease evolution in individual melanoma patients.
Methods
Sample collection and DNA extraction. Recruitment to the CASCADE (CAncer
tiSsue aCquisition After DEath rapid autopsy programme at the Peter MacCallum
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Cancer Centre followed approved protocols (PMCC Human Research Ethics
Committee approval number 11/102). Informed written consent was obtained from
all patients and families. Rapid autopsies were performed as previously described22.
See Supplementary Methods for further details.
Formalin-fixed paraffin-embedded (FFPE) tissues were sectioned 20 times and
the 1st, 10th and 20th sections underwent haematoxylin & eosin (H&E), Melan-A
and S100 staining, respectively, for identification by an expert histopathologist of
intra-tumoural regions of viable melanoma. Only samples that contained >70%
tumour content were used for DNA extraction and sequencing. After macro-
dissection and DNA extraction (QIAamp DNA FFPE Tissue Kit, Qiagen), each
sample was assessed for DNA integrity64. In cases where adjacent fresh frozen
samples were available for DNA extraction (DNeasy blood and tissue kit, Qiagen),
tumour content was verified using digital PCR for BRAF mutations65. Genomic
DNA from buffy coats (used as matching germline DNA) was extracted using the
DNeasy blood and tissue kit (Qiagen). Plasma DNA was extracted from 1–2 ml of
plasma (QIAamp Circulating Nucleic Acid Kit, Qiagen).
Whole exome sequencing. 100 ng to 1 ug of input DNA was fragmented using a
Covaris S2 focal acoustic device to an average fragment size of 180–220 bp (duty
cycle: 10%; intensity: 5; cycles per burst: 200; time: 3 min). Libraries were prepared
using KAPA Hyper Prep Kits for Illumina, (Kapa Biosystems) with SureSelect XT
adaptors and primers (Agilent Technologies). 6 or 9 PCR cycles were used for good
quality or FFPE-derived DNA, respectively. Hybridisation capture was performed
with SureSelect Human All Exon V5 or V6 (Agilent). Three indexed libraries were
run per lane on an Illumina HiSeq2500 platform (paired-end 100 bp).
Whole-genome sequencing. 100 ng of input DNA was fragmented as above to an
average size of 350 bp (duty cycle: 5%; intensity: 5; cycles per burst: 200; time: 50
seconds). Libraries were prepared using the TruSeq Nano DNA Library Prepara-
tion Kit (Illumina). Libraries were sequenced at The Kinghorn Centre for Clinical
Genomics (Sydney, Australia) on a HiSeq X Ten (Illumina). One sample was
sequenced per lane or over several lanes (paired-end 150 bp) to a depth of 30X or
60X for germline or tumour, respectively.
Calling and validation of somatic SNVs and small indels. After trimming and
quality filtering, sequencing reads were aligned to the human reference genome
(hg19) using bwa mem, deduplicated, realigned and scores recalibrated. Reads with
a mapping quality below 30 were removed. SNVs and small insertions/deletions
(indels) were called using an ensemble approach with multiSNV66 (minimum
average read coverage across samples of 10X), VarScan67 (minimum allele fre-
quency of 10%), muTect68 and IndelGenotyper69. SNVs flagged as ‘pass’ and
‘normal contamination’ by multiSNV were kept for further processing. SNVs with
an allele fraction >5% in the germline DNA were discarded. Variants in regions of
low coverage (<10x), repetitive/artefactual regions, off-target regions (for WES),
and that overlapped with healthy population databases were filtered out. Variants
detected by at least two callers and passing all filters were kept for downstream
analysis.
Given that the set of variants called for each patient was usually represented in
multiple samples, the following steps were applied to optimise the reliability of
variant calling. First, to exclude the possibility of absent variants due to insufficient
depth of sequencing, variants were filtered out if the region was regarded as low
coverage (<10x) in any sample of that patient, including the germline DNA.
Second, to leverage the sensitivity of muTect in samples of low cellularity, variants
absent in samples based on the procedure above but called only by muTect were
included. Third, to leverage the sensitivity of multiSNV as a multi-sample variant
caller, the presence of variants detected as above was confirmed in other samples
from the same patient via a lenient execution of VarScan (i.e. allowing variant allele
frequencies <10%, minimum coverage of 10x and variant present in ≥2 reads).
Mutational signatures were estimated using deconstructSigs70 with the
COSMIC v3 signatures set71. Validation of SNVs and small indels was performed
using the 48.48 Access Array system (Fluidigm). See Supplementary Methods for
further details.
Somatic copy number alteration and structural variant calling. We defined
structural variants (SVs) as mutations that involved a segment of DNA ( > 50nt)
differing between a tumour sample and the normal sample, caused by one or more
double stranded DNA breaks. These included insertions, deletions, tandem or
inverted duplications, inversions, translocations or copy number alterations
(CNAs). When the evidence of an SV was derived from CNA data alone, we used
the term CNA.
Estimates of allele-specific copy number, tumour cellularity and ploidy within
each sample were obtained using Sequenza72 (v2.1.0), followed by manual
verification. Large SVs (>1000nt) were detected using the GRIDSS (Genomic
Rearrangement Identification Software Suite; v1.3.2)73. See Supplementary
Methods for further details.
Phylogenic analysis. MEDICC74 (downloaded July 2014) was used to infer phy-
logenies from allele-specific copy number calls summarised at the cytogenetic
band level. To infer phylogenies from SNVs, a binary matrix of mutations
excluding regions of shared LOH was constructed for each patient. To infer
phylogenies from all mutations, a character-weighted binary supermatrix was
constructed. Maximum parsimony phylogenies were constructed using TNT (v1.5)
from these matrices75. See Supplementary Methods for further details.
Copy number validation. Fluorescence in situ hybridisation (FISH) was performed
for six CASCADE patients on FFPE slides to validate copy number results. Myc/
CEP8 and CCND1/CEP11 probes were used to validate allelic amplifications and
CDKN2A/CEP9 probes were used to validate allelic losses. For each slide, the area
to be scored was identified at low (10x) magnification using a DAPI filter. A
minimum of 100 cells from at least three random fields was scored for the number
of probe-specific alleles (red) and centromere (green) signals at high (100x)
magnification.
Inference of genome doubling. To test if the patterns of increased ploidy were due
to stochastic aneuploidy alone (stochastic gains of individual chromosomes) or if
WGD also played a role, two branching process-based models were fitted to the
data. The first modelled aneuploidy as the stochastic breakage and mis-segregation
of chromosomes at the arm-level. The second modelled aneuploidy in the same
way, together with a single WGD event.
The evolutionary history of each tumour genome was divided into N arbitrary
time periods. Each copy of each arm was assigned a fixed probability α of
undergoing a deletion, β of not changing, and γ of being duplicated within each
time period, and was subject to the constraint that α+β+γ=1. The WGD model
included a single WGD event after M time intervals (M ≤N). We used probability
generating functions to algebraically construct the probabilities of every possible
copy number state as polynomials depending on α, β, γ and N for the model with
no WGD and α, β, γ, N and M for the model with WGD. The generating functions
grow exponentially and are prohibitively large for N and M much greater than
about 5. To construct the generating function, we developed an efficient program
in the sage language (http://www.sagemath.org/) and utilised memoization to
reduce computational time and memory consumption. This program only needed
to be run once. We selected N= 6, permitting arm-level copy numbers up to 256 to
be modelled.
The parameters α, β, γ, and M for the two models were estimated for each
patient using maximum likelihood. To determine which model provided the most
likely explanation of the observed data, while correcting for the additional
parameter in the WGD model, we used the Akaike Information Criterion (AIC)76.
Unlike other information criteria, AIC does not rely upon any assumptions
contradicted by the model. In general, the model with WGD has 3 free parameters,
while the model without WGD has 2. In this case we also imposed α = γ, leading to
2 and 1 free parameters respectively. We applied the more general formula, leading
to a small constant offset of +2 to both AICWGD and AICnon-WGD, which does not
affect the relative likelihood or choice of best-fitting model.
Notably, our approach makes several assumptions that may limit its
applicability: the only events modelled are WGD and arm-level copy number
change (which are treated as independent events); a whole chromosome gain or
loss is modelled as a pair of independent arm-level events; focal amplification and
complex events are not included in the model; and resolution of event order is
limited to the N= 6 arbitrary time periods.
Code and additional details regarding the test are available at https://github.
com/PapenfussLab/Genome_doubling_test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Whole exome and genome sequencing data for CASCADE patients have been deposited
in the European Genome-Phenome Archive (EGA) under the study ID
EGAS00001004950. These data are available on request to the Peter MacCallum Cancer
Centre Data Access Committee (dac@petermac.org). Whole exome sequencing data from
patients MI-F, SK-G and SK-H19 are available via the National Center for Biotechnology
Information database of Genotypes and Phenotypes (NCBI dbGaP accession p). Whole
exome sequencing data from patients ETH-E, ETH-F and ETH-J21 are available on
request to Mitchell Levesque (Mitchell.Levesque@usz.ch). These patients did not give
their consent for the public availability of their raw sequencing data. The public release of
the data was not permitted at the time of collection under Swiss law. Repeat annotations
from Repeatmasker (http://www.repeatmasker.org/), known cancer genes from COSMIC
(https://cancer.sanger.ac.uk/cosmic), variants from EVS (http://evs.gs.washington.edu/
EVS) and 1000 Genomes (http://ftp.1000genomes.ebi.ac.uk/), and pathway information
from Reactome (https://reactome.org/) were also referenced in the study. All other data
are available within the Article, Supplementary Information or from the authors upon
request.
Code availability
All code developed for this in this study is publicly available: analysis pipeline (https://
github.com/PapenfussLab/CascadePipe), genome doubling test (https://github.com/
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PapenfussLab/Genome_doubling_test), and neoantigen analysis pipeline (https://github.
com/PapenfussLab/CascadeNeoPipe).
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